Skip to content
Sexuality – Lifestyle
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
April 22, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
April 14, 2026
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
April 14, 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
April 6, 2026
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
March 26, 2026
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
March 17, 2026
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
March 10, 2026
←
Previous Page
1
2
3